Press release

Advancing Breakthrough Research: Founders Secure Loan to Protect Pioneering Biotechnology Innovations

Cologne, September 2023 – In a significant step forward for neuroscience and biotechnology, Valeria Küpper and Dr. Elke Gabriel have secured a key financial loan to advance the patent protection of groundbreaking human brain organoid research. This development represents a pivotal moment in their mission to bring transformative solutions to neuroscience and drug development.

The funds will support the comprehensive patenting of innovative technologies that underpin the production of Hi-Q brain organoids and advanced retina solutions. These patent protections lay the foundation for what will become industry-leading technologies in neuroscience research and therapeutic development.

​

Securing the Future of Brain and Retina Research

Dr. Gabriel and Prof. Gopalakrishnan’s research focuses on creating scalable, physiologically relevant human brain organoids and retina models. These advancements offer unparalleled potential for replacing traditional animal models, accelerating drug discovery, and enabling researchers to decode complex disease mechanisms with human-specific systems.

 

Key innovations include:

• Hi-Q Brain Organoids: A robust, scalable, and cryopreserveable platform that produces highly homogeneous organoids. These models mimic the cell diversity and architecture of the human brain, making them ideal for disease modeling, drug screening, and therapeutic target identification.

• Advanced Retina Solutions: Featuring light-sensitive and cryopreserveable retina models derived from human stem cells, these solutions enable breakthroughs in vision-related disease modeling and drug testing.

 

A Game-Changer for Biotechnology

“Our mission has always been to push the boundaries of neuroscience by developing technologies that are both human-relevant and scalable,” said Dr. Elke Gabriel. “This loan allows us to secure the intellectual property needed to protect and scale these critical advancements.”

Valeria Küpper added, “These patents not only safeguard our innovations but also position us to deliver solutions that will redefine how the industry approaches brain and retina research. By making these tools accessible, we’re empowering scientists worldwide to tackle diseases that have long eluded effective treatment.”

 

Paving the Way for Transformative Applications

The technologies covered by these patents are poised to revolutionize neuroscience and pharmaceutical research, offering:

• Improved Disease Modeling: Human-relevant systems for studying neurological and retinal diseases with unprecedented accuracy.

• Enhanced Drug Discovery: Reliable platforms for testing drug efficacy and safety, reducing the reliance on animal models.

• Global Accessibility: Cryopreserveable and reculturable systems that can be shipped worldwide, ensuring broad accessibility for researchers.

 

For media inquiries, please contact:
contact@neuronfab.com